

POSTER SESSION I

1 March

Poster Board Number	ABSTRACT #	Presenter	TITLE
Correlates of Protection of Current Influenza Vaccines			
1	ACOR0010	Seiya Yamayoshi	Immunological correlates of prevention of the onset of seasonal H3N2 influenza
2	ACOR0012	Cheryl Cohen	Feasibility of assessing influenza vaccine efficacy and correlates of protection against infection and disease among children aged 6-23 months in South Africa
3	ACOR0017	Meng-Hsuan Sung	Assessment of humoral immune responses to repeated influenza vaccination in a multiyear cohort: a five-year follow-up
4	ACOR0026	George Okoli	Evidence from a comprehensive systematic review with meta-analysis suggests probable decline in seasonal influenza vaccine effectiveness with maturation of seasonal influenza vaccination program.
5	ACOR0028	Wey Wen Lim	Identifying correlates and mediators of protection against influenza and COVID-19 with causal mediation analysis
6	ACOR0034	Anne-Marie Rick	Timing of maternal influenza vaccine administration during pregnancy for optimal vaccine effectiveness in infants
7	ACOR0036	Juliet Dang	MF59-adjuvanted influenza vaccine for preventing cardio-respiratory hospitalizations in adults 65 years and older during the 2019-2020 U.S. influenza season
8	ACOR0048	Faith Ho	Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong: A Randomized Controlled Trial
9	ACOR0051	Sook-San Wong	Antibody landscapes to hemagglutinin and neuraminidase proteins of H3N2 influenza viruses in older adults
10	ACOR0062	David Hodgson	Identifying factors that drive post-vaccination Influenza serum HAI antibody titre dynamics
11	ACOR0077	Lirong Cao	Improving the prediction of influenza vaccine effectiveness by refined genetic distance measure
12	ACOR0082	Yang Ge	Impact of seasonal influenza vaccine dose on homologous and heterologous immunity
13	ACOR0095	Seema Lakdawala	Deciphering correlates of protection against airborne transmission of human seasonal H3N2 influenza virus transmission in the ferret model
14	ACOR0015	Joaquin Mould-Quevedo	Economic Impact of Influenza Vaccines on Hospitalization Costs for the US Elderly: A Real-World Economic Assessment of Adjuvanted Trivalent Influenza Vaccine Compared to Quadrivalent Standard-Dose Influenza Vaccine for the 2018-19 and 2019-20 Influenza Seasons
Epidemiology			
15	ACOR0014	Joaquin Mould-Quevedo	THE IMPACT OF THE INFLUENZA IMMUNIZATION RATE REDUCTION ON U.S. HOSPITAL SYSTEM RESOURCES. AN INFLUENZA AND COVID-19 CO-CIRCULATION APPROACH
16	ACOR0054	Nicole Wolter	Pre-season antibody titers and protection against influenza infection in a South African community cohort (PHIRST), 2016-2017
17	ACOR0057	Serena Marchi	Trends of influenza B/Yamagata antibodies from 2012/2013 to 2021/2022 in Italy in the context of potential lineage extinction
18	ACOR0065	Brendan Flannery	Hybrid approach to estimate influenza antibody titers associated with decreased risk of influenza
19	ACOR0076	Collrane Frivold	Evaluating the potential cost effectiveness of maternal influenza vaccination by administration trimester in Nepal: A modeling study
20	ACOR0086	Julia Rogers	Receipt of seasonal influenza vaccines in homeless shelters in King County, WA (USA) during the 2019-2020, 2020-2021 influenza seasons
21	ACOR0088	Derrick Bary Abila	Knowledge, attitude and practices of poultry handlers towards avian influenza in communities surrounding L. Victoria, Uganda
22			
23	ACOR0092	Joshua Nealon	Determinants of COVID-19 mRNA booster vaccine effectiveness and waning against the Omicron variant: a systematic review and meta-regression analysis
24	ACOR0103	Nicole Ngai Yung Tsang	Assessing the feasibility of a participatory daily antigen rapid testing surveillance (DARTS) system for SARS-CoV-2 infection in Hong Kong
Correlates of Protection for Next Generation / Universal Influenza Vaccines			
25	ACOR0005	Christine Oshansky	A heterologous prime and boost vaccination strategy for induction of cross-protective immunity using stockpiled H5 influenza virus vaccines
26	ACOR0008	Giuseppe Sautto	Dissection of the human pre-existing HA-reactive antibody response to next generation COBRA influenza vaccines.
27	ACOR0009	Olga Pleguezuelos	Increase in IFN γ secretion by PBMCs as correlate of cellular protection against influenza infection
28	ACOR0011	Jonah Sacha	Cytomegalovirus vaccine vector-induced, effector memory T cells protect cynomolgus macaques from lethal aerosolized heterologous influenza challenge
29	ACOR0023	Andreas Handel	Quantification of influenza antibody vaccine responses accounting for both vaccine strength and breadth
30	ACOR0029	Nedzad Music	Bicistronic self-amplifying mRNA (sa-mRNA) vaccines targeting seasonal influenza A viruses are protective and immunogenic in a ferret model
31	ACOR0035	Adrian Creanga	Neutralization profiling of anti-HA stem influenza antibodies with panel of representative influenza viruses
32	ACOR0041	Mohammad Abdul Aleem	Influenza vaccine and immune correlates of secondary protection against adverse acute cardiovascular events: a review and suggestions for future research on next generation influenza vaccine
33	ACOR0043	Pamuk Bilsel	Immune Response Profile Induced by Live M2SR (M2-Deficient Single Replication) Influenza Vaccine and Protection Against Human Challenge with a Substantially Drifted H3N2 Strain
34	ACOR0045	Ted Ross	Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019
35	ACOR0053	Sophie Valkenburg	Antibody effector functions are increased by seasonal vaccination for pandemic influenza viruses but baseline differences determine infection
36	ACOR0072	Eva-Maria Strauch	Consensus-Sequence Structural Immunogen Design (CoSSID).
37	ACOR0074	Jonathan Heeney	Immune correlates of a broadly protective H1N1 Influenza Vaccine
38	ACOR0087	Clara J. Sei	A Composite Influenza Peptide Vaccine Comprised of Highly Conserved Hemagglutinin, Neuraminidase and Matrix Protein Epitopes Induced Broad Serum Antibodies to Seasonal and Pandemic Influenza Strains
39	ACOR0094	Tsai-Chuan Weng	Analysis the immunogenic effects of site-specific glycosylation on the Gansu H7N9 HA protein

POSTER SESSION II

2 March

Poster Board Number	ABSTRACT #	Presenter	TITLE
Immune Responses and Immunological Assays for Influenza			
1	ACOR0006	Kalee Rumfelt	A rapid and flexible microneutralization assay for serological assessment of influenza viruses
2	ACOR0018	Greg Kirchenbaum	ImmunoSpot assays enable in-depth assessment of B cell reactivity against SARS-CoV-2 and seasonal influenza
3	ACOR0020	Aisha Souquette	Integrated Drivers of Basal Immunity and Acute Responses to Influenza Infection in Diverse Human Populations
4			
5	ACOR0032	Larisa Gubareva	Antigenic analysis of influenza hemagglutinin using a streamlined neutralization assay IRINA
6	ACOR0038	Jie-Long He	A rapid distinction of the potential zoonotic risk of avian influenza virus by a modified hemagglutination test
7	ACOR0046	Sook-San Wong	Antibody landscapes of H7N9 patients from wave 1 to wave 5 in China and its association with autoimmune markers
8	ACOR0055	Bingyi Yang	Quantifying the breadth of cross-reactive antibody responses to influenza A(H3N2)
9	ACOR0060	Nigel Temperton	An integrated serological platform for immunogenicity readouts and the elucidation of potential correlates of protection for influenza haemagglutinin- and neuraminidase-based vaccines
10	ACOR0066	Vivek Shinde	Towards an Improved Wild-type Sequence Based Hemagglutination Inhibition Assay for the Evaluation of Influenza Vaccines: Challenges and New Developments.
11	ACOR0083	IRINA V USTYUGOVA	Assessment of Neuraminidase Antibody Responses to an Octavalent Influenza mRNA vaccine using a Multiplex Neuraminidase SeroAssay
12	ACOR0090	Stephany Sanchez-Ovando	Transcriptomic profiling of vaccination versus Post-Influenza infection
13	ACOR0093	Sarah Larteley Lartey Jalloh	Dissecting the longevity and cross-reactive antibody responses after quadrivalent inactivated influenza vaccine immunization in children
Regulatory Challenges for Next Generation of Influenza Vaccines			
14	ACOR0075	Galina Landgraf	Study of oligonucleotide polymorphisms of the influenza virus using high-resolution melting (HRM) analyzing of PCR products.
Correlates of Protection for SARS-CoV-2 and Broadly Protective Coronavirus Vaccine			
15	ACOR0004	Camila Coelho	B CELL MEMORY RESPONSES TO FOUR DIFFERENT COVID-19 VACCINE PLATFORMS
16	ACOR0007	Kei Miyakawa	Rapid detection of SARS-CoV-2 neutralizing immunity
17	ACOR0016	Claudia Maria Trombetta	OVERVIEW OF HUMORAL IMMUNE RESPONSE TO SARS-CoV-2 VARIANTS IN PATIENTS AND VACCINEES FOLLOWING HOMOLOGOUS AND HETEROLOGOUS VACCINATIONS
18	ACOR0022	Takuya Hemmi	Intranasal vaccine with ODN2006 as an adjuvant induces cross-protective secretory IgA antibodies against SARS-CoV-2 variants, reducing the potential risk of lung eosinophilic immunopathology.
19	ACOR0037	Kelsey Sumner	Protection Against COVID-19 Outpatient Illness by Level of SARS-CoV-2 Receptor Binding Domain Binding Antibody at the Time of Illness, U.S. Flu VE Network
20	ACOR0042	Benjamin Cowling	Immune responses to COVID-19 vaccines among healthcare workers in Hong Kong
21	ACOR0047	Sheena Sullivan	SARS-CoV-2 antibody responses are better for mRNA versus adenoviral vector (AdV) vaccines: results from a cohort of Australian healthcare workers
22	ACOR0049	Sheena Sullivan	Antibody and B cell cross-reactivity and kinetics following asymptomatic versus symptomatic SARS-CoV-2 infection
23	ACOR0056	Michael Watt	Estimating the health-related quality of life benefit of prophylactic treatment for COVID-19 in immunocompromised people
24	ACOR0063	Harriet Ware	Protective effectiveness of prior SARS-CoV-2 infection and hybrid immunity against Omicron infection and severe disease: a systematic review and meta-regression
25	ACOR0068	Nancy Hiu Lan Leung	Serologic correlates of protection against infection of COVID-19 vaccines: preliminary findings from a randomised trial of homologous and heterologous inactivated and mRNA third-dose vaccination (the Cobovax study)
26	ACOR0073	Kylie Konrath	Immune-focused SARS-CoV-2 nanoparticles interrogate antibody specificity and protection
27	ACOR0078	Elaine Shuo Feng	Antibody correlates of protection against symptomatic SARS-CoV-2 infection for Alpha, Delta, Gamma and Zeta variants: analysis from two randomized controlled trials in the UK and Brazil
28	ACOR0080	Carol Weiss	Assessment of the correlation between SARS-CoV-2 serum neutralization titers and post-vaccination infections among healthcare workers from the Prospective Assessment of Seroconversion (PASS) Study
29	ACOR0081	Paolo Cantaloni	Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose
30	ACOR0100	Emily Martin	Lack of correlation between pre-Omicron wave antibody titers and Omicron infection measured by pseudovirus neutralization activity against the original vaccine strain